glp 1 drugs and vision loss GLP-1 are associated with a 35% higher risk of NAION, an eye condition that can cause sudden loss. About 6 to 10 extra cases per 10,000 users over 3 years 💉GLP-1s have taken the world

Int J Obes (Lond) 45(5):923933 Acknowledgements We thank all the VIIH investigators, clinical research staff, and especially the patients for helping to collect these data

Although overall findings support a cardioprotective effect of GLP-1 RAs, the ITCA 650 trial showed directionally higher hazard ratios for several outcomes

FDA Law Blog [blog on the Internet]

The Global Epidemiology of NAFLD and NASH in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis

What are the research priorities for idiopathic intracranial hypertension

For instance, Wegovy is a GLP-1 RA specifically approved for weight loss while also being researched for other medical uses such as metabolic conditions